Article Text

Download PDFPDF
P-selectin glycoprotein ligand-1 VNTR polymorphisms and risk of thrombosis in the antiphospholipid syndrome
  1. Reyhan Diz-Kucukkaya1,
  2. Murat Inanc2,
  3. Vahid Afshar-Kharghan3,
  4. Q Ed Zhang4,
  5. José A López5,
  6. Yuksel Pekcelen1
  1. 1
    Division of Hematology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
  2. 2
    Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
  3. 3
    Thrombosis Research Section, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
  4. 4
    Pre-Award Research Office, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
  5. 5
    Puget Sound Blood Center, University of Washington School of Medicine, Seattle, Washington, USA
  1. Reyhan Diz-Kucukkaya, MD, Mesa Yamacevler Sitesi, Akasya 5 blok, D6, Gokturk, 34490, Istanbul-Turkey; rkucukkaya{at}hotmail.com

Abstract

Objectives: Antiphospholipid antibodies (aPLA) have been shown to enhance thrombus formation by increasing the expression of adhesive receptors such as P-selectin on endothelial cells. The P-selectin counter-receptor on leucocytes is P-selectin glycoprotein ligand-1 (PSGL-1). We have previously described a variable number of tandem repeats (VNTR) polymorphism in the mucin-like region of PSGL-1, with three alleles: allele A, 16 repeats; allele B, 15 repeats; and allele C, 14 repeats.

Methods: We compared the PSGL-1 VNTR allele and genotype frequencies in 90 patients with antiphospholipid syndrome (APS) with thrombosis, 39 patients with persistent aPLA positivity without thrombosis, and 203 healthy controls.

Results: The frequency of the B allele was significantly higher in patients with APS with thrombosis compared with patients without thrombosis (p = 0.023). When we compared the groups by genotype frequencies, we found a markedly higher frequency of the AB genotype in patients with APS with thrombosis than in aPLA-positive patients without thrombosis (38.9% vs 10.3%, p = 0.001) or in normal population (38.9% vs 22.2%, p<0.01).

Conclusions: We suggest that the VNTR polymorphism of PSGL-1 is a significant determinant of thrombotic predisposition in patients with APS. Furthermore, risk appears to correlate best with the combination of alleles inherited rather than with the presence of any particular allele.

  • antiphospholipid syndrome
  • P-selectin
  • P-selectin glycoprotein ligand-1
  • PSGL-1 VNTR polymorphism
  • thrombosis

Statistics from Altmetric.com

Footnotes

  • This work was supported by the Research Fund of the Istanbul University (Project number: T-967/19022001), TUBA-GEBIP (R.D.K./TUBA-GEBIP/2004-15), and by a grant from National Institutes of Health of the United States (Grant number RO1HL65205).

  • Competing interests: None declared.

  • Abbreviations:
    aPLA
    antiphospholipid antibodies
    APS
    antiphospholipid syndrome
    PSGL-1
    P-selectin glycoprotein ligand-1
    VNTR
    variable number of tandem repeats